Pentadeca Arginate vs BPC-157
Side-by-side comparison of Pentadeca Arginate, BPC-157 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery | BPC-157 Body Protection Compound-157 Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Pentadecapeptide Arginine Analogue | Gastric Pentadecapeptide |
| Amino acids | 15 | 15 |
| Molecular weight | 1,476.6 Da | 1,419.5 Da |
| Half-life | ~4–6 hrs (estimated) | ~4 hrs (SC) |
| Route(s) | Subcutaneous, Intramuscular, Oral (research) | Subcutaneous, Intramuscular, Oral (research only) |
| Mechanism & Research | ||
| Primary mechanism | PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… |
| Research status | Research Compound | Research Compound |
| Evidence summary | PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… |
| Protocol & Dosing | ||
| Typical dose | 200–500 mcg per injection | 200–500 mcg per injection |
| Frequency | Once or twice daily | Once or twice daily |
| Duration | 4–12 weeks | 4–12 weeks |
| Timing | Near injury site when possible; any time | Near injury site when possible |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S0) | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | BPC-157, TB-500, GHK-Cu | TB-500, GHK-Cu, KPV, Pentadeca Arginate |
| Full profile | Read full Pentadeca Arginate profile → | Read full BPC-157 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.